ExonHit Therapeutics, a French drug and diagnostic discovery company, and bioMérieux, a major player in the field of in vitro diagnostics, announce today that they have reached an important research milestone in the diagnosis of breast cancer.
Nachrichten
bioMérieux receives De Novo FDA Authorization for its BIOFIRE® Joint Infection (JI) Panel
04 Mai, 2022Joint infections (“septic arthritis”) are serious infections involving either native or prosthetic joints. They are medical emergencies which can occur at all ages, and can lead to functional joint impairment, long-lasting disability, and may even be life-threatening. The number of prosthetic...
bioMérieux launches an avian flu test for research purposes
02 Februar, 2006
As a major player in the field of in vitro diagnostics, bioMérieux confirms its commitment to the fight against emerging diseases and launches its avian flu detection test.
bioMérieux Editions publishes a book on hospital-acquired infections
09 November, 2005
bioMérieux annonce la parution d’un ouvrage consacré aux Infections Liées aux Soins (ILS). Ce livre a été élaboré par les professeurs Marie-Laure Joly-Guillou et Bernard Régnier. Le Docteur Jean Carlet en a signé la préface.
bioMérieux and ExonHit Therapeutics Extend their Strategic Collaboration
13 Oktober, 2005
bioMérieux and ExonHit announced today that they signed an agreement to extend their collaboration for six years for the discovery and development of new blood diagnostics in the area of early cancer detection.
DiagnoSwiss and bioMérieux announce that they have signed an exclusive license agreement for the development and use of DiagnoSwiss electrochemical microchips in human in vitro diagnostics
27 Juli, 2005
Monthey (Switzerland) – bioMérieux and DiagnoSwiss announced today that DiagnoSwiss has granted bioMérieux with an exclusive worldwide license under the patent rights of DiagnoSwiss relating to the development, manufacturing and marketing of electrochemical microchips in the field of human in vitro diagnostics.
Hepanostika® HBsAg Ultra – New “ultra”-sensitive test for Hepatitis B infection from bioMérieux
05 Juli, 2005
bioMérieux, a world leader in the field of in vitro diagnostics, announces the launch of its new microelisa assay for the detection of hepatitis B surface antigen. Hepanostika® HBsAg Ultra is officially presented at the XV European Regional Congress of the International Society of Blood Transfusion (ISBT) currently being held from July 2-6 in Athens, Greece.
Hospices Civils de Lyon and bioMérieux inaugurate a joint immunogenomics and inflammation unit
23 Juni, 2005
Hospices Civils de Lyon (HCL) and bioMérieux will inaugurate today the “HCL-bioMérieux” joint unit dedicated to research in immunogenomics and inflammation. The unit is headed by Prof. Pierre Miossec and Bruno Mougin.
MRSA ID - bioMérieux’s latest contribution to the fight against nosocomial infections
25 Mai, 2005
A world leader in the field of in vitro diagnostics, bioMérieux SA announces the launch of a new product for rapid, reliable identification of Methicillin-Resistant Staphylococcus aureus, a common cause of nosocomial infections.
Roche Diagnostics and bioMérieux announce that Roche has granted non exclusive rights for cardiac markers NT-proBNP to bioMérieux
29 April, 2005
Roche Diagnostics and bioMérieux announced today, that bioMérieux has been granted a nonexclusive license agreement under the patent rights of Roche Diagnostics relating to the development, manufacturing and marketing of immunoassays that detect a key cardiac marker of congestive heart failure and acute coronary syndrome.